Penumbra Past Earnings Performance
Past criteria checks 1/6
Penumbra has been growing earnings at an average annual rate of 15.8%, while the Medical Equipment industry saw earnings growing at 11.4% annually. Revenues have been growing at an average rate of 17.3% per year. Penumbra's return on equity is 1.2%, and it has net margins of 1.3%.
Key information
15.8%
Earnings growth rate
12.7%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 17.3% |
| Return on equity | 1.2% |
| Net Margin | 1.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Penumbra (NYSE:PEN) May Have Issues Allocating Its Capital
Oct 06
Penumbra Grinding Through A Painful Growth Expectations Reset
Aug 20What You Can Learn From Penumbra, Inc.'s (NYSE:PEN) P/S
Aug 01Penumbra, Inc. (NYSE:PEN) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jul 11Returns At Penumbra (NYSE:PEN) Appear To Be Weighed Down
Jun 19Penumbra: Appeal Improves As Operating Leverage Continues
May 30Penumbra, Inc.'s (NYSE:PEN) Earnings Haven't Escaped The Attention Of Investors
Apr 12Estimating The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)
Mar 21Some Investors May Be Worried About Penumbra's (NYSE:PEN) Returns On Capital
Jan 23A Look At The Fair Value Of Penumbra, Inc. (NYSE:PEN)
Nov 16Penumbra: Appeal Improves, Just Not Appealing Yet
Oct 16Returns On Capital Signal Tricky Times Ahead For Penumbra (NYSE:PEN)
Oct 05Penumbra: Consolidation Does Nothing To Change Long-Term Thesis, Reiterate Buy
Sep 01A Look At The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)
Aug 15Penumbra (NYSE:PEN) Has Some Way To Go To Become A Multi-Bagger
Jun 28Penumbra: Future Upside Drivers In Fundamental, Sentimental And Valuation Factors
Jun 22Getting In Cheap On Penumbra, Inc. (NYSE:PEN) Might Be Difficult
Jun 02We're Not Worried About Penumbra's (NYSE:PEN) Cash Burn
Apr 01Penumbra Non-GAAP EPS of $0.16 beats by $0.01, revenue of $221.22M beats by $4.19M
Feb 23Penumbra Riding Higher On Upcoming Launches And Rerating
Jan 12Penumbra: Today's Best Medical Equipment Nearby Cap-Gain Buy
Nov 03Penumbra cut to Neutral at Citi on macro concerns
Oct 05Penumbra, Asahi team up to bring blood clot removing device Indigo to Japan
Sep 22Penumbra stock rises ~11% after announcing European launch of catheters for stroke care
Sep 07Revenue & Expenses Breakdown
How Penumbra makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,134 | 14 | 537 | 92 |
| 31 Mar 24 | 1,096 | 93 | 528 | 89 |
| 31 Dec 23 | 1,059 | 91 | 506 | 84 |
| 30 Sep 23 | 995 | 41 | 492 | 80 |
| 30 Jun 23 | 938 | 29 | 475 | 81 |
| 31 Mar 23 | 885 | 6 | 462 | 79 |
| 31 Dec 22 | 847 | -2 | 450 | 79 |
| 30 Sep 22 | 830 | -31 | 439 | 81 |
| 30 Jun 22 | 806 | -19 | 425 | 76 |
| 31 Mar 22 | 782 | -6 | 401 | 74 |
| 31 Dec 21 | 748 | 5 | 378 | 105 |
| 30 Sep 21 | 710 | 34 | 376 | 81 |
| 30 Jun 21 | 671 | 16 | 358 | 90 |
| 31 Mar 21 | 592 | -5 | 327 | 93 |
| 31 Dec 20 | 560 | -16 | 287 | 88 |
| 30 Sep 20 | 539 | -10 | 285 | 72 |
| 30 Jun 20 | 527 | 11 | 278 | 60 |
| 31 Mar 20 | 556 | 39 | 286 | 53 |
| 31 Dec 19 | 547 | 48 | 273 | 52 |
| 30 Sep 19 | 523 | 45 | 259 | 50 |
| 30 Jun 19 | 495 | 15 | 245 | 45 |
| 31 Mar 19 | 471 | 12 | 232 | 40 |
| 31 Dec 18 | 445 | 7 | 226 | 36 |
| 30 Sep 18 | 420 | 9 | 216 | 34 |
| 30 Jun 18 | 392 | 28 | 207 | 33 |
| 31 Mar 18 | 363 | 13 | 196 | 33 |
| 31 Dec 17 | 334 | 5 | 184 | 32 |
| 30 Sep 17 | 311 | -7 | 174 | 29 |
| 30 Jun 17 | 294 | 5 | 166 | 28 |
| 31 Mar 17 | 279 | 9 | 158 | 26 |
| 31 Dec 16 | 263 | 15 | 148 | 24 |
| 30 Sep 16 | 245 | 18 | 136 | 23 |
| 30 Jun 16 | 228 | 6 | 125 | 21 |
| 31 Mar 16 | 205 | 3 | 115 | 20 |
| 31 Dec 15 | 186 | 1 | 102 | 18 |
| 30 Sep 15 | 167 | 0 | 92 | 17 |
| 30 Jun 15 | 149 | -1 | 82 | 16 |
| 31 Mar 15 | 138 | -1 | 72 | 15 |
| 31 Dec 14 | 126 | -1 | 64 | 16 |
| 31 Dec 13 | 89 | 1 | 45 | 14 |
Quality Earnings: PEN has a large one-off loss of $100.0M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: PEN's current net profit margins (1.3%) are lower than last year (3.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PEN's earnings have grown by 15.8% per year over the past 5 years.
Accelerating Growth: PEN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PEN had negative earnings growth (-51.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (8.5%).
Return on Equity
High ROE: PEN's Return on Equity (1.2%) is considered low.